Evidence map›Paper›PMID 40837643›Full record

ArticleAfrican health sciences2025

Tugce Unalan-Altintop, Selay Demirci-Duarte, Ozgen Koseoglu-Eser, Aycan Gundogdu, Aslı Cakar, Revasiye Gulesen, Belkıs Levent, Belgin Altun, Banu Sancak, Deniz Gür

Abstract read
In one paragraph

Article in African health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Invasive Non-typhoidalInfectious diseases & clinical microbiology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tugce Unalan-AltintopHacettepe University, Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey.
Selay Demirci-DuarteHacettepe University, Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey.
Ozgen Koseoglu-EserHacettepe University, Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey.
Aycan GundogduErciyes University, Faculty of Medicine Department of Medical Microbiology, Kayseri, Turkey.
Aslı CakarHacettepe University, Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey.
Revasiye GulesenTurkish Public Health Agency, Department of Microbiology Reference Laboratories, Ankara, Turkey.
Belkıs LeventTurkish Public Health Agency, Department of Microbiology Reference Laboratories, Ankara, Turkey.
Belgin AltunHacettepe University, Vocational School of Health Services, Ankara, Turkey.
Banu SancakHacettepe University, Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey.
Deniz GürHacettepe University, Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Increase in antimicrobial resistance poses a global threat for treatment of Salmonellosis. Objectives: In this study, serovar distribution, antimicrobial susceptibility, resistance genes, and clonal diversity were characterized in clinical Methods: In this study, serovar distribution of clinical Results: The serovars were Conclusions: A relative decrease in resistance to trimethoprim-sulfamethoxazole was detected with time. Trimethoprim-sulfamethoxazole and azithromycin can be good alternatives to the widely-used ciprofloxacin and third-generation cephalosporins. High resistance of colistin and ciprofloxacin may be due to the extensive use of antibiotics in poultry, which highlights the significance of one health concept.

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialDrug Resistance, Multiple, BacterialSalmonellaSalmonella InfectionsFemaleHumansMaleMicrobial Sensitivity TestsMolecular EpidemiologySalmonella enteritidisSerogroupTertiary Care CentersTurkeyAnti-Bacterial AgentsciprofloxacincolistinESBLPFGESalmonellatrimethoprim-sulfamethoxazole

Identifiers

PMID40837643
PMCPMC12361946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.